XML 89 R79.htm IDEA: XBRL DOCUMENT v3.21.2
BUSINESS COMBINATIONS AND ASSET ACQUISITIONS - Business Combinations Textual (Details)
$ / shares in Units, $ in Thousands
1 Months Ended 3 Months Ended 9 Months Ended 19 Months Ended
Jun. 23, 2021
USD ($)
Apr. 14, 2021
USD ($)
$ / shares
shares
Jan. 05, 2021
USD ($)
$ / shares
shares
Mar. 03, 2020
USD ($)
Jan. 31, 2021
shares
Sep. 30, 2021
USD ($)
Jun. 30, 2021
USD ($)
Mar. 31, 2021
USD ($)
Sep. 30, 2020
USD ($)
Mar. 31, 2020
USD ($)
Sep. 30, 2021
USD ($)
Sep. 30, 2021
USD ($)
Sep. 30, 2020
USD ($)
Sep. 30, 2021
USD ($)
Mar. 03, 2021
USD ($)
Dec. 31, 2020
USD ($)
Business Acquisition [Line Items]                                
Contingent consideration           $ 363,647         $ 363,647 $ 363,647   $ 363,647   $ 2,477
Stock-based compensation expense           63,600     $ 41,500   283,300   $ 111,100      
Business combination, equity interest in acquiree, remeasurement gain                     30,500   0      
Stock-based compensation                     197,180   111,075      
Cash payments to acquire business, net of cash acquired                     415,549   6,658      
Issuance of common stock for business combination and asset acquisition             $ 16,120 $ 1,254,798 $ 250 $ 28,597 1,270,918   28,847      
Equity interests issued or issuable to previous investors       $ 8,400                        
Thrive                                
Business Acquisition [Line Items]                                
Investment owned, at fair value     $ 12,500                          
Business combination, equity interest in acquiree, remeasurement gain                         7,600      
Change in amount of contingent consideration liability                         $ 10,500      
Investment Income | Thrive                                
Business Acquisition [Line Items]                                
Business combination, equity interest in acquiree, remeasurement gain               30,500                
Ashion Analytics                                
Business Acquisition [Line Items]                                
Total purchase price   $ 109,999                            
Business acquisition, equity interest issued or issuable (in shares) | shares   125,444                            
Shares issued, price per share (in usd per share) | $ / shares   $ 129.33                            
In-process research and development (IPR&D)   $ 39,000                            
Weighted-average remaining useful life of finite-lived intangible asset (in years)   13 years                            
Acquisition related costs                     1,600          
Fair value of stock issued in acquisition   $ 16,200                            
Common stock issued   16,224                            
Cash   74,775                            
Ashion Analytics | Commercial Launch Milestone                                
Business Acquisition [Line Items]                                
Additional cash consideration to be paid   20,000                            
Contingent consideration   19,000                            
Ashion Analytics | MRD Product Revenue Milestone                                
Business Acquisition [Line Items]                                
Contingent consideration   30,000                            
Revenue milestone   $ 500,000                            
Thrive                                
Business Acquisition [Line Items]                                
Total purchase price     $ 2,187,054                          
Business acquisition, equity interest issued or issuable (in shares) | shares     9,323,266   9,300,000                      
Shares issued, price per share (in usd per share) | $ / shares     $ 127.79                          
Contingent consideration     $ 450,000                          
Acquisition related costs               10,300     10,300          
Fair value of stock issued in acquisition     1,190,000                          
Common stock issued     1,175,431                          
Payments to acquire businesses and accelerated vesting of awards     590,200                          
Cash     584,996                          
Stock-based compensation expense     166,000                          
Compensation consideration assumed     197,000                          
Compensation consideration assumed and allocated to consideration transferred     52,200                          
Compensation consideration assumed and deemed compensatory     144,800                          
Accelerated vesting compensation expense     65,000                          
Unrecognized compensation expense     $ 79,800                          
Share conversion ratio (share per share)     0.06216                          
Business combination, pro forma loss           39,600           219,600        
Stock-based compensation           4,500         19,000          
Additional benefit charges           1,200         3,900          
Thrive | Employees with Qualifying Termination Events                                
Business Acquisition [Line Items]                                
Accelerated vesting compensation expense               13,500                
Thrive | Fair Value                                
Business Acquisition [Line Items]                                
Contingent consideration     $ 352,000                          
Thrive | General and Administrative Expense                                
Business Acquisition [Line Items]                                
Incremental share based compensation expense     16,000                          
Stock-based compensation expense     5,200                          
Accelerated vesting compensation expense               $ 86,200                
Thrive | FDA Approval                                
Business Acquisition [Line Items]                                
Contingent consideration     150,000                          
Thrive | CSM Coverage                                
Business Acquisition [Line Items]                                
Contingent consideration     300,000                          
Thrive | Allocated to Consideration Transferred | Fair Value                                
Business Acquisition [Line Items]                                
Contingent consideration     331,300                          
Thrive | Allocated to Previous Ownership Interest | Fair Value                                
Business Acquisition [Line Items]                                
Contingent consideration     6,400                          
Thrive | Allocated to Compensation | Fair Value                                
Business Acquisition [Line Items]                                
Contingent consideration     14,300                          
Thrive | Compensation Expense                                
Business Acquisition [Line Items]                                
Contingent payment obligations     $ 18,200                          
Paradigm & Viomics                                
Business Acquisition [Line Items]                                
Total purchase price       40,400                        
In-process research and development (IPR&D)       7,800                     $ 7,800  
Common stock issued       32,200                        
Cash payments to acquire business, net of cash acquired       $ 8,200                        
Issuance of common stock for business combination and asset acquisition                           28,800    
Amount of shares held for future issuance           $ 3,400         $ 3,400 $ 3,400   $ 3,400    
Equity interests issued or issuable to previous investors, vesting period       4 years                        
Paradigm & Viomics | Acquired developed technology                                
Business Acquisition [Line Items]                                
Weighted-average remaining useful life of finite-lived intangible asset (in years)       15 years                        
PFS Genomics                                
Business Acquisition [Line Items]                                
Total purchase price $ 33,569                              
In-process research and development (IPR&D) $ 33,074